Need “One on One” Support for Your GLP-1 Plan?

---

“Without it.. you may regain about a pound per month after you stop using the medication.”

Since sustainable weight control can be a chronic biological condition, any overweight individual and those with weight-related disorders normally benefit greatly from one-on-one coaching for identifying supportive lifestyle changes. For starters, a protein-forward daily menu that delivers this important macronutrient by following a rhythmic daily-eating plan helps trigger the natural release of appetite-suppressing effects to combat the return of the hunger hormone ghrelin.

Moreover, preserving muscle during GLP-1 medical weight loss is critical to maintain physical strength during rapid weight loss to protect metabolic pathways and reduce risk of weight regain. Our one-on-one weight loss coach at MRC Pueblo can help you identify and make changes to your routines that can make it easier to keep the weight off long-term, instead of regaining it as subcutaneous or visceral body fat. Whereas muscle tissue is heavier, it can burn calories even at rest.

So, how does muscle mass use energy to work?

Although muscle mass does not burn fat directly, one pound of muscle burns about three times the calories each day when your body is at rest, compared to the calories burned by a pound of fat. After all, muscle tissue is metabolically-active and has to use more energy (calories) just to maintain itself. So, working out routinely helps to build lean muscle tissue for burning extra calories, as well as helps you reach and maintain a target weight for healthy living. It is important to remember that fat doesn’t vanish just because you have muscle, as it is your caloric balance that signals when your body burns fat for fuel.

How Do GLP-1 Meds Differ from the Natural Gut Hormone?

Yes. For starters, GLP-1 receptor agonists do not stimulate the body to produce more of its own natural hormone. Instead, the synthetic compound directly binds to and activates GLP-1 receptors, slowing the gastric emptying of food into the digestive tract and increasing feelings of fullness (satiety) by regulating blood sugar levels. The body's natural incretin hormone is released in the small intestine approximately 10 to 15 minutes after eating, but it breaks down rapidly in the bloodstream. Synthetic GLP-1s, by contrast, were designed to resist degradation and remain metabolically-active for longer periods of time with added benefits.

Were GLP-1 Incretin Mimetics Developed for Weight Loss?

No. GLP-1 receptor agonists were not originally developed specifically for weight loss. The incretin mimetics were originally designed to help individuals manage Type 2 diabetes. The weight-loss effects of pharmaceutical GLP-1 emerged as a notable side effect that was documented during early clinical trials. GLP-1 incretin mimetics help regulate blood sugar by triggering insulin release and blocking glucagon secretion from the liver. But, after subsequent clinical observations reinforced the unexpected results, the FDA approved key GLP-1s for treating obesity and overweight, along with other weight-related health conditions.

Was Semaglutide the First GLP-1 Receptor Agonist?

No. Semaglutide was not the first GLP-1 receptor agonist approved by the FDA for medical use. That milestone belongs to exenatide (brand name Byetta), which received FDA approval in 2005. Here’s a brief timeline of key GLP-1 receptor agonist approvals:

• Exenatide (Byetta) – First GLP-1 receptor agonist approved by the FDA (2005) to help treat Type 2 diabetes by improving blood sugar control alongside diet and exercise.
• Liraglutide – First GLP-1 RA specifically approved for chronic weight management as well as type 2 diabetes and cardiovascular risks that was approved over a decade ago.
• Semaglutide* – More recently approved; it is now one of the most widely prescribed weight-loss medications in history. This single-action GLP-1 is available as both a weekly injection and a daily oral pill.
• Tirzepatide – First dual-action incretin mimetic, combining GLP-1 with glucose-dependent insulinotropic polypeptide (GIP) for a compounded hormonal effect that produces greater weight reduction in some individuals.

*Semaglutide was initially approved under the brand name Ozempic for type 2 diabetes, well after the GLP-1 class was already established for improving blood sugar control for managing specific metabolic disorders like cardiovascular disease.

Do GLP-1 Meds Require Similar Lifestyle Changes as Bariatric Surgery?

No. While both GLP-1 medications and bariatric surgery require healthy eating habits and regular physical activity, the lifestyle adjustments are not identical in scope or permanence. Bariatric surgery demands stricter, permanent rules due to the altered digestive system anatomy. For example:

• GLP-1 Medications involve smaller meal sizes driven by delayed stomach emptying to reduce appetite and overall calorie intake. There are no permanent mechanical restrictions and no severe “dumping syndrome” triggers as commonly seen post-surgery.

• Bariatric Surgery relies on permanent anatomical changes to restrict food intake. Without ongoing mindful behavioral habits, weight can gradually return even after surgery. In addition, nutritional supplementation is a lifelong need due to bypassed intestinal absorption pathways for nutrients.

The most effective chronic weight management plans are multifactorial. Both surgical and pharmaceutical interventions should include behavioral support mechanisms to help patients transition from their starting point toward their target goals. Rapid weight loss without meaningful behavioral adjustments, whether through surgery or medication, typically results in weight regain once the primary intervention is reduced or stopped.

It is also worth noting that different GLP-1 formulations appear to work differently across individuals, underscoring the importance of personalized treatment plans, as stopping use of the drug typically restores natural hunger cues and those annoying food cravings that can cause rapid weight regain.

_______________________

A recent study at Stanford Medical says GLP-1 receptor agonist may not work well for everyone due to potential genetic variances that affect how a man or woman’s body is less able to lower blood sugar levels effectively due to “GLP-1 Resistance.” In part, this may be due to the fact that GLP-1 RAs do not cause the body to release its own version of the natural glucagon-like peptide-1 hormone. But many GLP-1 users who were asked said they could have benefited from more tools, resources and targeted support during their medical weight loss journey. At Metabolic Research Center Pueblo, our goal is to provide the GLP-1 support needed to create a customized program that preserves crucial muscle mass, limits the common side effects of using a GLP-1 receptor agonist, and produces the changes your body needs for sustainable weight control.